Article info

Download PDFPDF
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Authors

  • Carmen Garcia-Duran Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Francisco Grau Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Guillermo Villacampa Oncology Data Science (ODysSey) VHIO, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Ana Oaknin Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Ana Oaknin, Gynaecologic Cancer Programme, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; aoaknin{at}vhio.net
View Full Text

Citation

Garcia-Duran C, Grau F, Villacampa G, et al
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Publication history

  • Accepted March 25, 2022
  • First published April 20, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.